Favorable prognostic value of SOCS2 and IGF-I in breast cancer
Authors:
- Michael C HaffnerMHMichael C Haffner
- Barbara PetridouBPBarbara Petridou
- Jean Phillipe PeyratJPJean Phillipe Peyrat
- Françoise RévillionFRFrançoise Révillion
- Elisabeth Müller-HolznerEMElisabeth Müller-Holzner
- Günter DaxenbichlerGDGünter Daxenbichler
- Christian MarthCMChristian Marth
- Wolfgang DopplerWDWolfgang Doppler
Open Access
- 25 July 2007
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 136
Abstract
Background: Suppressor of cytokine signaling (SOCS) proteins comprise a protein family, which has initially been described as STAT induced inhibitors of the Jak/Stat pathway. Recent in vivo and in vitro studies suggest that SOCS proteins are also implicated in cancer. The STAT5 induced IGF-I acts as an endocrine and para/autocrine growth and differentiation factor in mammary gland development. Whereas high levels of circulating IGF-I have been associated with increased cancer risk, the role of autocrine acting IGF-I is less clear. The present study is aimed to elucidate the clinicopathological features associated with SOCS1, SOCS2, SOCS3, CIS and IGF-I expression in breast cancer. Methods: We determined the mRNA expression levels of SOCS1, SOCS2, SOCS3, CIS and IGF-I in 89 primary breast cancers by reverse transcriptase PCR. SOCS2 protein expression was further evaluated by immuno-blot and immunohistochemistry. Results: SOCS2 expression inversely correlated with histopathological grade and ER positive tumors exhibited higher SOCS2 levels. Patients with high SOCS2 expression lived significantly longer (108.7 vs. 77.7 months; P = 0.015) and high SOCS2 expression proved to be an independent predictor for good prognosis (HR = 0.45, 95% CI 0.23 – 0.91, P = 0.026). In analogy to SOCS2, high IGF-I expression was an independent predictor for good prognosis in the entire patient cohort. In the subgroup of patients with lymph-node negative disease, high IGF-I was a strong predictor for favorable outcome in terms of overall survival and relapse free survival (HR = 0.075, 95% CI 0.014 – 0.388, P = 0.002). Conclusion: This is the first report on the favorable prognostic value of high SOCS2 expression in primary mammary carcinomas. Furthermore a strong association of high IGF-I expression levels with good prognosis was observed especially in lymph-node negative patients. Our results suggest that high expression of the STAT5 target genes SOCS2 and IGF-I is a feature of differentiated and less malignant tumors.Keywords
This publication has 49 references indexed in Scilit:
- Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survivalBreast Cancer Research and Treatment, 2006
- Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinomaJournal of Clinical Pathology, 2005
- Epigenetic inactivation of SOCS‐1 by CpG island hypermethylation in human gastric carcinomaInternational Journal of Cancer, 2004
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- SOCS-1 and SOCS-3 Block Insulin Signaling by Ubiquitin-mediated Degradation of IRS1 and IRS2Journal of Biological Chemistry, 2002
- Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesisOncogene, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Cloning and Characterization of Novel CIS Family GenesBiochemical and Biophysical Research Communications, 1997
- Prognosis in Stage II “T1N1M0”Breast CancerAnnals of Surgery, 1981